Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
273
-
Total 13F shares, excl. options
-
141M
-
Shares change
-
-6.27M
-
Total reported value, excl. options
-
$5.09B
-
Value change
-
-$215M
-
Put/Call ratio
-
0.28
-
Number of buys
-
128
-
Number of sells
-
-144
-
Price
-
$36.02
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q3 2025
331 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q3 2025.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 273 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 141M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (13.1M shares), FMR LLC (12.5M shares), VANGUARD GROUP INC (12.3M shares), RA CAPITAL MANAGEMENT, L.P. (12M shares), BlackRock, Inc. (9.96M shares), T. Rowe Price Investment Management, Inc. (8.32M shares), WELLINGTON MANAGEMENT GROUP LLP (5.03M shares), STATE STREET CORP (4.79M shares), D. E. Shaw & Co., Inc. (4.29M shares), and Paradigm Biocapital Advisors LP (3.78M shares).
This table shows the top 273 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.